Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday.

Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceuticals’ Phase 3 CARDIO-TTRansform trial—evaluating their drug Wainua in transthyretin amyloid cardiomyopathy (ATTR-CM)—confirmed an earlier top-line failure, but alarmed investors with an unexpectedly negative outcome in combination therapy.

The trial revealed that pairing Wainua with TTR stabilizers—the current standard of care dominated by Pfizer’s Vyndaqel—was actually associated with worse outcomes than standard care alone, delivering a primary-endpoint relative risk of 1.14. By contrast, Wainua performed well as a standalone therapy, with a relative risk of 0.71.

Because Alnylam’s commercially approved Amvuttra (vutrisiran) and its next-generation pipeline candidate nucresiran rely on a similar genetic mechanism to silence transthyretin production in the liver, the results sent shockwaves through the sector.

Biotech analysts spent Friday morning parsing the wreckage, debating whether the failure signals a broader flaw in combining RNA silencers with stabilizers or if Alnylam can pivot its upcoming trial strategy to avoid a similar fate.

A Striking Combo Failure

Analyst reactions ranged from cautious optimism regarding Alnylam’s distinct platform to blunt warnings about the necessity of immediate clinical changes.

Jefferies analyst Faisal Khurshid framed the findings as a fundamental challenge to the clinical necessity of RNA silencers in a market where oral stabilizers already dominate. He noted that the trial showed "limited benefit for silencers in a stabilizer-treated population" and viewed the readout as a neutral-to-negative readthrough for Alnylam that adds pressure to its flagship TTR franchise.

"The role of silencers seems unclear in a world where stabilizers are standard of care, and there is limited evidence to use silencers over easy-to-use oral stabilizers," Mr. Khurshid wrote in a note to clients, adding that the results "reinforce TRITON-CM risk" for Alnylam’s pipeline.

Stifel analyst Paul Matteis similarly called the combination outcome “clearly worse than expected” and warned that Wall Street should not rely on unproven hypotheses to assume Alnylam is immune.

"While minimal benefit was largely expected for the eplontersen/tafamidis combo arm... it’s an incremental surprise to see that the combination had a hazard ratio of 1.14—clearly worse than expected," Mr. Matteis wrote. "Bottom line: the data paint a confusing picture and there isn’t anything obvious to point to that would make us confident that the nucresiran study... is derisked."

Mr. Matteis argued that the "unequivocal" failure in combination therapy leaves Alnylam with little choice but to proactively alter the design of its Phase 3 TRITON-CM study for nucresiran. He noted that Alnylam could benefit by "biasing further enrollment towards monotherapy, and/or modifying the statistical hierarchy where nucresiran monotherapy could serve as the primary outcome."

Is Alnylam Differently Positioned?

Oppenheimer analyst Kostas Biliouris took a more constructive stance, pointing out key biological and trial-design differences between the two drugmakers. He highlighted that the negative signal seen in Wainua—an antisense oligonucleotide—has not been observed in trials for Alnylam’s RNA-interference (siRNA) platform.

"Wainua treatment was associated with elevated primary-endpoint RR (1.14) in patients with baseline stabilizer use vs. monotherapy (RR=0.71), suggesting potential safety signals... that haven’t been observed with Amvuttra/siRNA+stabilizer, thus increasing TRITON-CM Probability of Success," Mr. Biliouris wrote.

Mr. Biliouris added that Alnylam’s platform achieved roughly 10% greater TTR knockdown in its landmark HELIOS-B trial than Ionis achieved in CARDIO-TTRansform. Still, he cautioned that a "lack of clear winning scenario could press ALNY near-term" until management provides clarity on trial adjustments.

Wall Street Eyes the Commercial Shield

Despite the turmoil in clinical pipeline expectations, analysts largely agreed that Alnylam’s immediate commercial foundation remains secure.

Because real-world prescription of Amvuttra is predominantly driven by treatment-naïve patients receiving monotherapy—rather than combination treatments—the commercial impact is expected to be minimal. Physicians are also unlikely to extrapolate negative combination data from a rival’s trial into their everyday prescribing of Amvuttra.

Stifel reiterated its confidence in Alnylam’s long-term commercial target, noting that accelerated diagnosis rates for ATTR-CM position Amvuttra to eventually reach $10 billion in peak sales.

For now, investor focus shifts squarely to Alnylam management, with Wall Street expecting swift updates on how the company plans to insulate its pipeline from the fallout in Munich.